Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Abroad (travel likely)RecruitingPHASE2

Conditions

Metastatic/Locally Advanced Small-Cell Lung Cancer · Metastatic/Locally Advanced Poorly Differentiated NEC · Metastatic/Locally Advanced High-grade MTC

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Gustave Roussy, Villejuif, France
Contact: Study coordinator (Yohann Loriot, MD, PhD) · Yohann.LORIOT@gustaveroussy.fr · +33 (0)1 42 11 42 11
Contact: Study coordinator (Fernanda Mosele, MD) · mariafernanda.mosele@gustaveroussy.fr

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Solid Tumor, Adult · Colorectal Cancer · NSCLC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Gilbert, United States · La Jolla, United States

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China